Category Archives: – Pharma

The Medical Advocate

Posted in - Opinion, - Pharma, - Policy, - Reviews, books, devices, CDC, CMS, Congress, FDA, NIH | Comments Off on The Medical Advocate

The new CDC guidelines for prescribing opioid pain pills

June 1, 2016- Interviewed by Steven E. Greer, MD Pain pill prescriptions have quadrupled since the 1990’s as drug companies stepped up marketing and funded

Posted in - JAMA, - NEJM, - Pharma, CDC, Emergency medicine, General surgery, Oncology, Psychology Psychiatry, Rehab, Spine surgery, Sports medicine | Leave a comment

Essay: Opioids coming through the Mexican border are a national security risk

Update January 8, 2019- President Trump quoted from this story tonight during his talk from the Ova

Posted in - Opinion, - Pharma, - Policy, CDC, Congress, FDA, NIH, Primary care medicine, Rehab | Leave a comment

Daily aspirin once again proves to be of no use and also deadly

Update January 13, 2015- Yet another study was published highlighting the risks of daily aspirin. 

Posted in - JAMA, - Pharma, - Policy, Cardiac surgery, Cardiology, Gastroenterology and liver, General surgery, Neurology, Neurosurgery, Oncology, Primary care medicine | Leave a comment

Triple Therapy for Cystic Fibrosis

October 18, 2018- interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Pharma, FDA, Genetics, Infectious disease, Internal Medicine, National Jewish Health, Pediatrics, Pulmonology | Leave a comment

“You’re telling me this now?” Why the news is suddenly critical of statins and antidepressants

Opinion: February 19, 2012  By Steven Greer, MD The CBS news show “60 Minutes” made waves with a story asserting that the antidepressants

Posted in - Opinion, - Pharma, - Policy, Congress, FDA | Leave a comment

Why are suicide rates increasing along with increased usage of antidepressants?

June 8, 2018- Fox News’ Tucker Carlson interviewed author Johan Hari about his book Lost Connections and the

Posted in - Pharma, - Policy, CDC, FDA, Neurology, Primary care medicine, Psychology Psychiatry | Leave a comment

Steven E. Greer, MD, on CNBC discussing antidepressants

June 8, 2018– In the news recently are the suicide deaths of Kate Spade and Anthony Bourdain.

Posted in - Pharma, FDA, Psychology Psychiatry | Leave a comment

TV Quack Dr. David Agus still likes daily aspirin despite heart guidelines dropping it

March 23, 2019

Posted in - Pharma, Cardiology, CDC, FDA, Oncology | Comments Off on TV Quack Dr. David Agus still likes daily aspirin despite heart guidelines dropping it

President-elect Trump adopts plan by The Healthcare Channel to bring back drug manufacturing jobs

September 4, 2010- by Steven Greer, MD The Commissioner of the FDA, Margaret Hamburg, could become the single biggest job creator

Posted in - Opinion, - Pharma, - Policy, CMS, Congress, FDA | Leave a comment

BRAF and MEK combos for melanoma

Update October 1, 2015- The FDA approved the use of two drugs, Opdivo and Yervoy, to treat metastatic melanoma, as we first discussed with Dr.  Ribas last year.

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Once again, daily aspirin is shown to be deadly rather than beneficial

September 16, 2018- by Steven E. Greer, MD The Healthcare Channel has been pounding the table for many years pushing back against the drug

Posted in - NEJM, - Pharma, Cardiac surgery, Cardiology, Gastroenterology and liver, Geriatrics, Internal Medicine, Neurology, Neurosurgery, Oncology, Vascular Surgery | Leave a comment

Industry conflicts arise at PCORI threatening any real comparative effectiveness research

February 7, 2014- By Steven E. Greer, MD The Patient Centered Outcome Research Institute (PCORI) was created by the PPACA “ObamaCare” law in 2010.

Posted in - Medical Devices, - Opinion, - Pharma, CMS, Congress, Yale | Leave a comment

Review of immunotherapy and targeted therapy

June 17, 2016- interviewed by Steven E. Greer, MD We interviewed Siwen Hu-Lieskovan MD, PhD of UCLA, an expert with immunotherapies for melanoma, to go over the

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

The Year in Review: 2018

December 29, 2018- by Steven E. Greer, MD The biggest stories this year related

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy, - Reviews, books, devices, - The Weekly Summary | Leave a comment

Insurance companies are not paying for Repatha and Praluent

Update November 2, 2018- Amgen slashed the annual cost of this drug to $6,000.

Posted in - Biotech, - Pharma, - Policy, Cardiac surgery, Cardiology, Henry Ford, Primary care medicine | Leave a comment

Ocrelizumab (Ocrevus) versus Placebo in Primary Progressive Multiple Sclerosis

January 31, 2017- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Pharma, Neurology, Univ Texas | Leave a comment

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

February 27, 2017- interviewed by Steven E. Greer, MD We interviewed Joaquim Bellmunt, MD, PhD, the Director of the Bladder Cancer Center at Dana-Farber,

Posted in - Biotech, - NEJM, - Pharma, Harvard, Oncology | Leave a comment

KIT inhibition by Gleevec (imatinib) for severe asthma

May 26, 2017- Interviewed by Steven E. Greer, MD Novartis’ Gleevec (imatinib) was approved in the U.S. in 2001 to treat leukemia. Now, researchers

Posted in - Biotech, - NEJM, - Pharma, National Jewish Health, Pulmonology | Leave a comment

Antoni Ribas, MD discusses cancer drugs targeting the PD1 signaling pathways

March 19, 2013- Interviewed by Steven E. Greer, MD The upcoming ASCO meeting will be dominated by numerous presentations relating to new

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment